Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry

Risankizumab, a monoclonal antibody targeting interleukin-23, is approved for the treatment of Crohn’s disease (CD). Real-world evidence on its effectiveness remains limited. We assessed 1-year effectiveness and safety of risankizumab in a prospective cohort of patients with CD, emphasizing difficult-to-treat disease.